2nd Middle East Camp for Parkinson's, Movement Disorders and Neuromodulation: From Neurodegeneration to Neuroregeneration

Doha, Qatar
January 29-31, 2015

Course Description

Doha, QatarThe fields of Parkinson's disease and Movement Disorders are under served in the Middle East region which span numerous countries and includes a population of over 500 million inhabitants. The understanding of Parkinson's disease and Movement Disorders is rapidly evolving and numerous therapeutic medical and surgical treatment options are available on the market.

The Second Middle East Camp for Parkinson's, Movement Disorders and Neuromodulation is the follow-up to the popular First Middle East Camp that took place in Dubai in 2014. The course is intended to provide up-to-date discussions on Parkinson's disease and other movement disorders and all available advance therapies in the field. The course will also focus on unmet needs in more detail based on course evaluations.

Learning Objectives

At the conclusion of this activity, you should be able to accomplish the following:

  • Better understand the clinical phenomenology of motor and non-motor symptoms in Parkinson’s disease
  • Better understand Neurodegeneration in Parkinson’s disease and atypical Parkinsonsim
  • Better understand future role of biomarkers in Parkinson disease diagnosis, treatment and neuroprotection
  • Better understand clinical diagnosis and role of imaging in Parkinson’s disease
  • List the treatments available for the management of motor and non-motor symptoms of Parkinson’s disease
  • Better understand clinical phenomenology of non Parkinsonian Movement Disorders
  • Better understand treatment of non Parkinsoniam Movement Disorders
  • Provide an overview on selection process of candidates for pump therapies in advanced Parkinson's disease
  • Provide an overview of the selection process of candidates for deep brain stimulation (DBS) in movement disorders – especially Parkinson’s disease, dystonia, and tremor – and outline the efficacy and associated risks for DBS. This includes knowledge about the different brain targets used for DBS and their effects on specific symptoms along with DBS programming
  • Better understand role of gene therapy and stem cell therapy in Parkinson’s disease
  • Discuss role of botulinum toxin therapy for movement disorders
Recommended Audience

This course is recommended for Movement disorder neurologists, General neurologists, Geriatricians, Neurosurgeons, Allied health professionals and Neurologists-in-training.

Registration Opens Soon

Associate Membership

Attendees at this course will qualify to apply for a complimentary 1-year MDS membership that includes:

  • Access to the “members only” website resources and online journals
  • Reduced registration rate for future courses and International Congress
  • Quarterly Newsletter, Moving Along
  • Access to online MDS Membership Directory

Following the course all those who qualify for this offer will be emailed a link to apply for associate membership.  Once approved, benefits will begin immediately.

Learn More

For more information, email MDS Education.